E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or th-repertoires or on the immune response induced or sustained after immunization with E7 protein

Virology

Volumn 231, Issue 1, 1997, Pages 155-165

  Herd, K ^a   Fernando, G J P ^a   Dunn, L A ^a   Frazer, I H ^a   Lambert, P ^b   Tindle, R W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; ONCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPIDERMIS; IMMUNIZATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; SKIN; TRANSGENIC MOUSE;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS MUSCULUS; PAPILLOMAVIRUS;

EID: 0030961437     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8491     Document Type: Article

References (30)

1. Gissmann L. Papillomavirus and human oncogenesis. Curr. Genet. Dev. 2:1992;97-102.
2. Koutsky L. A., Kiviat N. B. Genital infectious agents and invasive cervical cancer. Lancet. 342:1993;184-185.
3. Straight S. W., Herman B., McCance D. J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69:1995;3185-3192.
4. McIntyre M. C., Ruesch M. N., Laimins L. A. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology. 215:1996;73-82.
5. Lambert P. F., Pan H., Pitot H. C., Liem A., Jackson M., Griep A. E. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. USA. 90:1993;5583-5587.
6. Frazer I. H., Lieppe D. M., Dunn L. A., Liem A., Tindle R. W., Fernando G. J. P., Phelps W. C., Lambert P. F. Immunological responses in HPV16 E6-E7 transgenic mice 16 E7 protein correlate with the presence if skin disease. Cancer Res. 55:1995;2635-2639.
7. Selvey L. A., Dunn L. A., Tindle R. W., Park D. S., Frazer I. H. Human papillomavirus (HPV) type 18E7 protein in a short-lived steroid inducible phosphoprotein in HPV-transformed cell lines. J. Gen. Virol. 7:1994;1647-1653.
8. Williams I. R., Ort R. J., Kupper T. S. Keratinocyte expression of B7.1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natl. Acad. Sci. USA. 91:1994;12780-12784.
9. Bal V., McIndoe A., Denton G., Hudson D., Lombardi G., Lamb J. Antigen presentation by keratinocytes induces tolerance in human T-cells. Eur. J. Immunol. 23:1990;1956-1962.
10. Miller J. F. A. P., Flavell R. A. T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr. Opin. Immunol. 6:1994;892-899.
11. b. J. Virol. 68:1994;4049-4052.
12. b. J. Immunol. 126/1:1981;317-321.
13. Alonso de Velasco E., Dekker H. A. T., Antal P., Jalink J. P., van Strijp J. A. G., Verheul A. F. M., Verhoef J., Snippe H. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines. Vaccine. 12:1994;1419-1422.
14. Tindle R. W., Smith J. A., Geysen H. M., Selvey L. A., Frazer I. H. Identification of B-epitopes in human papillomavirus (HPV) 16 E7 open reading frame (ORF) protein. J. Gen. Virol. 71:1990;1347-1354.
15. Tindle R. W., Fernando G. J. P., Sterling J. C., Frazer I. H. A public T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA. 88:1991;5887-5891.
16. de Moerloose P., Frazer I., Sewell I., Collins E., MacKay I. Cell-mediated immunity to hepatitis B virus antigens in mice; correlation ofin vivoin vitro. Clin. Exp. Immunol. 64:1986;285-294.
17. Griep A. E., Herber R., Jeon S., Lohse J. K., Dubielzig R. R., Lambert P. F. Tumorigenicity by Human Papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol. 67:1993;1373-1384.
18. Demers G. W., Foster S. A., Halbert C. L., Galloway D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is by-passed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA. 91:1994;4382-4386.
19. Campbell A. Monoclonal antibody technology. Laboratory Techniques in Biochemistry and Molecular Biology. 1980;Elsevier, Amsterdam.
20. 12. Clin. Exp. Immunol. 101:1995;265-271.
21. Feltkamp M. C. W., Smits H. L., Vierboom M. P. M., Minnaar R. P., de Jough B. M., Drijhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T-lymphocyte epitope-containing peptide protects against a tumour induced by human papillomavirus 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
22. Slebos R. J. C., Lee M. H., Plunkett B. S., Kessis T. D., Williams B. O., Jacks T. p53 G1 arrest involves pRB related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA. 91:1994;5320-5325.
23. Von Knebel Doeberitz H., Rittmuller C., Aengeneyndt F., Jansen Durr P., Spitovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for pheno-type and E6-p53 and E7-pRB interactions. J. Virol. 68:1994;2811-2821.
24. Tindle R. W., Frazer I. H. Human pathogenic papillomaviruses. Curr. Topics Microbiol. Immunol. 18:1994;217-252.
25. Chen L., Thomas E. K., Hu S-L., Hellstrom I., Hellstrom K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumour rejection antigen. Proc. Natl. Acad. Sci. USA. 88:1992;110-114.
26. Pfister H. Biology and biochemistry of papillomaviruses. Pharmacol. 99:1984;111-181.
27. Gaspari A., Katz S. Induction and functional characterization of class 2 MHC Ia antigens on murine keratinocytes. J. Immunol. 6:1994;8992-8999.
28. Kast W. M., Offringa R., Peters P. J., Voordouw A., Meleon R. H., Van der Eb A. J., Melief C. J. M. Eradication of adenovirus E1 induced tumours by EIA-specific cytotoxic T-lymphocytes. Cell. 59:1989;603-614.
29. Toes R. E. M., Blom R. J. J., Offringa R., Kast W. M., Melief C. J. M. Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:1996;3911-3918.
30. Strom T. B., Roy-Choudbury P., Manfro R., Zheny X. X., Nickerson P. W., Wood K., Bushell A. The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol. 8/5:1996;688-693.